Niraparib: Phase III data

Top-line data from the double-blind, international Phase III NOVA trial in about 597 platinum-sensitive ovarian cancer patients who received >=2 prior platinum chemotherapy lines showed that once-daily 300 mg oral niraparib met

Read the full 328 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE